Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.
Adams RA, Fisher DJ, Graham J, Seligmann JF, Seymour M, Kaplan R, Yates E, Parmar M, Richman SD, Quirke P, Butler R, Brown E, Collinson F, Falk S, Wasan H, Shiu KK, Middleton G, Samuel L, Wilson RH, Brown LC, Maughan TS; FOCUS4 Trial Investigators.
Adams RA, et al. Among authors: seligmann jf.
J Clin Oncol. 2021 Nov 20;39(33):3693-3704. doi: 10.1200/JCO.21.01436. Epub 2021 Sep 13.
J Clin Oncol. 2021.
PMID: 34516759
Free PMC article.
Clinical Trial.